Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.

Martin SS, Qasim A, Reilly MP.

J Am Coll Cardiol. 2008 Oct 7;52(15):1201-10. doi: 10.1016/j.jacc.2008.05.060. Review.

2.
3.

Cardiovascular effects of leptin.

Sweeney G.

Nat Rev Cardiol. 2010 Jan;7(1):22-9. doi: 10.1038/nrcardio.2009.224. Epub 2009 Dec 1. Review.

PMID:
19949425
4.

Leptin and the cardiovascular system.

Rahmouni K, Haynes WG.

Recent Prog Horm Res. 2004;59:225-44. Review.

PMID:
14749504
5.

Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease.

Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D.

Curr Hypertens Rep. 2008 Apr;10(2):131-7. Review.

PMID:
18474180
6.

Leptin, obesity and cardiovascular disease.

Correia ML, Haynes WG.

Curr Opin Nephrol Hypertens. 2004 Mar;13(2):215-23. Review.

PMID:
15202616
7.

[Leptin--adipose tissue hormone and its role in cardiovascular diseases].

Racek-Król B.

Pol Merkur Lekarski. 2006 Jun;20(120):713-6. Review. Polish.

PMID:
17007277
8.

Leptin resistance and diet-induced obesity: central and peripheral actions of leptin.

Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA.

Metabolism. 2015 Jan;64(1):35-46. doi: 10.1016/j.metabol.2014.10.015. Epub 2014 Oct 23. Review.

PMID:
25497342
9.

Leptin signaling and obesity: cardiovascular consequences.

Yang R, Barouch LA.

Circ Res. 2007 Sep 14;101(6):545-59. Review.

10.

Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis.

Kshatriya S, Reams GP, Spear RM, Freeman RH, Dietz JR, Villarreal D.

Curr Opin Nephrol Hypertens. 2010 Jan;19(1):72-8. doi: 10.1097/MNH.0b013e328332fb49. Review.

PMID:
19851106
11.

Leptin and cardiovascular diseases.

Luo JD, Zhang GS, Chen MS.

Drug News Perspect. 2005 Sep;18(7):427-31. Review.

PMID:
16362081
12.

Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Holvoet P.

Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Review.

PMID:
18669160
14.

Recent advances in the relationship between obesity, inflammation, and insulin resistance.

Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B.

Eur Cytokine Netw. 2006 Mar;17(1):4-12. Review.

15.

Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players.

Zimmet P, Boyko EJ, Collier GR, de Courten M.

Ann N Y Acad Sci. 1999 Nov 18;892:25-44. Review.

PMID:
10842650
16.

Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications.

Mark AL, Correia ML, Rahmouni K, Haynes WG.

J Hypertens. 2002 Jul;20(7):1245-50. Review.

PMID:
12131511
17.

Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome.

Correia ML, Rahmouni K.

Diabetes Obes Metab. 2006 Nov;8(6):603-10. Review.

PMID:
17026484
18.

Novel molecular aspects of ghrelin and leptin in the control of adipobiology and the cardiovascular system.

Rodríguez A.

Obes Facts. 2014;7(2):82-95. doi: 10.1159/000360837. Epub 2014 Mar 26. Review.

19.

Leptin and cardiovascular diseases.

Hou N, Luo JD.

Clin Exp Pharmacol Physiol. 2011 Dec;38(12):905-13. doi: 10.1111/j.1440-1681.2011.05619.x. Review.

PMID:
21957899
20.

Peripheral metabolic actions of leptin.

Muoio DM, Lynis Dohm G.

Best Pract Res Clin Endocrinol Metab. 2002 Dec;16(4):653-66. Review.

PMID:
12468413

Supplemental Content

Support Center